Atlantic Union Bank fined $6.2 million by CFPB for illegal overdraft fee harvesting
The Consumer Financial Protection Bureau fined Atlantic Union Bank $6.2 million after it found the bank illegally enrolled thousands of customers in checking account overdraft programs, the regulator said Thursday.
"Atlantic Union Bank harvested millions of dollars in overdraft fees through a host of illegal practices," said CFPB Director Rohit Chopra, in a statement. "Americans are fed up with junk fee scams and the CFPB will continue its work to ensure families are treated fairly."
Atlantic Union Bank, is a subsidiary of Atlantic Union Bankshares Corp. (AUB)
"We respectfully disagree with the CFPB's conclusions about these historical practices and take very seriously our obligation to comply with applicable law," said Atlantic Union CEO John Asbury, in a press release.
"Nonetheless, we believe it is in Atlantic Union's best interest to settle this matter so we can continue focusing on providing the products, services, and support our customers want," he added.
-Chris Matthews
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-07-23 0923ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks